Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

451 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial.
Iacobelli S, de Wreede LC, Schönland S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N, Gahrton G; EBMT CMWP, Plasma Cell Disorders Subcommittee. Iacobelli S, et al. Among authors: bosi a. Bone Marrow Transplant. 2015 Apr;50(4):505-10. doi: 10.1038/bmt.2014.310. Epub 2015 Jan 26. Bone Marrow Transplant. 2015. PMID: 25621805 Clinical Trial.
High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors.
Majolino I, Corradini P, Scimè R, Falda M, Bosi A, Tarella C, Musso M, Olivieri A, Boccadoro M, Marcenò R, Santoro A, Pileri A. Majolino I, et al. Among authors: bosi a. Bone Marrow Transplant. 2003 May;31(9):767-73. doi: 10.1038/sj.bmt.1703924. Bone Marrow Transplant. 2003. PMID: 12732883 Clinical Trial.
BU/melphalan and auto-SCT in AML patients in first CR: a 'Gruppo Italiano Trapianto di Midollo Osseo (GITMO)' retrospective study.
Lemoli RM, D'Addio A, Marotta G, Pezzullo L, Zuffa E, Montanari M, De Vivo A, Bonini A, Galieni P, Carella AM, Guidi S, Michieli M, Olivieri A, Bosi A. Lemoli RM, et al. Among authors: bosi a. Bone Marrow Transplant. 2010 Apr;45(4):640-6. doi: 10.1038/bmt.2009.235. Epub 2009 Oct 5. Bone Marrow Transplant. 2010. PMID: 19802019
Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome.
Alessandrino EP, Porta MG, Malcovati L, Jackson CH, Pascutto C, Bacigalupo A, Teresa van Lint M, Falda M, Bernardi M, Onida F, Guidi S, Iori AP, Cerretti R, Marenco P, Pioltelli P, Angelucci E, Oneto R, Ripamonti F, Rambaldi A, Bosi A, Cazzola M; Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Alessandrino EP, et al. Among authors: bosi a. Am J Hematol. 2013 Jul;88(7):581-8. doi: 10.1002/ajh.23458. Epub 2013 May 30. Am J Hematol. 2013. PMID: 23606215 Free PMC article. Clinical Trial.
Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ⩾10 years.
Andreola G, Labopin M, Beelen D, Chevallier P, Tabrizi R, Bosi A, Michallet M, Santarone S, Ehninger G, Polge E, Laszlo D, Schmid C, Nagler A, Mohty M. Andreola G, et al. Among authors: bosi a. Bone Marrow Transplant. 2015 Dec;50(12):1508-12. doi: 10.1038/bmt.2015.193. Epub 2015 Sep 21. Bone Marrow Transplant. 2015. PMID: 26389832
Treatment of refractory chronic GVHD with rituximab: a GITMO study.
Zaja F, Bacigalupo A, Patriarca F, Stanzani M, Van Lint MT, Filì C, Scimè R, Milone G, Falda M, Vener C, Laszlo D, Alessandrino PE, Narni F, Sica S, Olivieri A, Sperotto A, Bosi A, Bonifazi F, Fanin R; GITMO (Gruppo Italiano Trapianto Midollo Osseo). Zaja F, et al. Among authors: bosi a. Bone Marrow Transplant. 2007 Aug;40(3):273-7. doi: 10.1038/sj.bmt.1705725. Epub 2007 Jun 4. Bone Marrow Transplant. 2007. PMID: 17549053 Free article.
WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
Alessandrino EP, Della Porta MG, Bacigalupo A, Van Lint MT, Falda M, Onida F, Bernardi M, Iori AP, Rambaldi A, Cerretti R, Marenco P, Pioltelli P, Malcovati L, Pascutto C, Oneto R, Fanin R, Bosi A; Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Alessandrino EP, et al. Among authors: bosi a. Blood. 2008 Aug 1;112(3):895-902. doi: 10.1182/blood-2008-03-143735. Epub 2008 May 22. Blood. 2008. PMID: 18497321 Free article.
Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation.
Crocchiolo R, Zino E, Vago L, Oneto R, Bruno B, Pollichieni S, Sacchi N, Sormani MP, Marcon J, Lamparelli T, Fanin R, Garbarino L, Miotti V, Bandini G, Bosi A, Ciceri F, Bacigalupo A, Fleischhauer K; Gruppo Italiano Trapianto di Midollo Osseo, Cellule Staminale Ematopoietiche (CSE) e Terapia Cellulare; Italian Bone Marrow Donor Registry. Crocchiolo R, et al. Among authors: bosi a. Blood. 2009 Aug 13;114(7):1437-44. doi: 10.1182/blood-2009-01-200378. Epub 2009 Jun 10. Blood. 2009. PMID: 19515726 Free article. Clinical Trial.
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, Crippa C, Boccadoro M, Perrone G, Falcone A, Nozzoli C, Zambello R, Masini L, Furlan A, Brioli A, Derudas D, Ballanti S, Dessanti ML, De Stefano V, Carella AM, Marcatti M, Nozza A, Ferrara F, Callea V, Califano C, Pezzi A, Baraldi A, Grasso M, Musto P, Palumbo A; GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) Italian Myeloma Network. Cavo M, et al. Blood. 2012 Jul 5;120(1):9-19. doi: 10.1182/blood-2012-02-408898. Epub 2012 Apr 12. Blood. 2012. PMID: 22498745 Free article. Clinical Trial.
451 results